Liposomal Bupivacaine vs Ropivacaine for TAPBs

Sun Yat-sen University74 enrolled

Overview

Few studies have compared the efficacy of ultrasound (US)-guided TAP blocks with Liposomal bupivacaine(LB) versus ropivacaine in reducing postoperative opioid usage in patients undergoing laparoscopic lower abdominal tumor Resection. Therefore, we are conducting this prospective, randomized controlled trial to compare the postoperative analgesic effects of LB and ropivacaine for TAP blocks among patients undergoing laparoscopic colorectal procedures.

This study aimed to investigate the impact of liposomal bupivacaine (LB) on postoperative opioid usage for ultrasound(US)-guided transversus abdominis plane (TAP) blocks in laparoscopic colorectal resections. We divided 76 patients into two groups. An injection of bilateral TAP blocks was administered to LB group using 133mg liposomal bupivacaine in each block (266mg total), and to R group using 20 ml 0.25% ropivacaine in each block (40 ml total). Opioid consumption and pain scores at 6h, 24h, 48h and 72h were recorded postoperatively, as well as the total intraoperative remifentanil dose, the hospital stay lengths after surgery, and adverse events including dizziness, nausea, and vomiting.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Abdominal Tumor Postoperative Analgesia Liposomal Bupivacaine Ropivacaine

Interventions

Liposomal BupivacaineDRUG

After induction of anesthesia, bilateral TAPB was performed under ultrasound guidance. The patients in the bupivacaine liposome group were injected with bupivacaine liposome 133mg(10ml+ 10ml 0.9% normal saline mixed into 20ml)/ point (two points in total).

RopivacaineDRUG

Patients in ropivacaine group were given 0.25% ropivacaine 20ml/ point (two points in total).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients undergoing laparoscopic resection of lower abdominal tumors 2. ASA grade II-III 3. Age: 18-70 years. Exclusion Criteria: 1. (1) The patient does not agree to participate in the clinical study 2. (2) The patient has a clear history of opioid tolerance or allergy 3. (3) The patient has a history of local anesthetic allergy 4. (4) Previous history of dementia, mental illness or other central nervous system diseases 5. (5) Have a history of chronic pain or are taking opioids and other analgesics 6. (6) Patients are generally in poor condition with a history of serious diseases of cardiovascular system, respiratory system, digestive system, urinary system or central nervous system, and may not survive for more than 3 months 7. (7) The patient had any of the following conditions in the 12 months before surgery: myocardial infarction, severe/unstable angina pectoris, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident, pulmonary embolism 8. (8) Pregnant women 9. (9) Unable to cooperate with follow-up or poor compliance 10. (10) Patients with acute myocardial infarction, cardiac arrest or shock during surgery or hospitalization 11. (11) ASA score above grade III.

Locations (1)

Jingdun Xie

Guangzhou, Guangdong, China

RECRUITING

Outcomes

Primary Outcomes

Postoperative opioid use

The amount of drug used in the postoperative analgesia pump

Time frame: 3 days postoperatively

Secondary Outcomes

Postoperative pain score

Postoperative VAS score

Time frame: 3 days postoperatively

Postoperative adverse reactions

Postoperative adverse reactions were followed up

Time frame: 3 days postoperatively

Central Contacts

Ping Yu

CONTACT

00-86-13631373286 yuping@sysucc.org.cn

Jingdun Xie

CONTACT

00-86-13560380116 xiejd@sysucc.org.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.